FIELD: pharmaceutics.
SUBSTANCE: present invention relates to a composition for preventing, improving or treating a neurological disorder or mental disorder, containing vesicles obtained from Lactobacillus paracasei, as an active ingredient. As a result of the research, it was found that when introducing vesicles obtained from Lactobacillus paracasei, transgenic animals with a model of a neurological disorder are effectively suppressed by disturbed neurocerebral function, as well as with the introduction of vesicles derived from Lactobacillus paracasei, to an animal with a model of mental disorder due to neuropsychic stress mental dysfunctions caused by stress and accompanying behavioral disturbances are effectively suppressed.
EFFECT: thus, according to the present invention, vesicles obtained from Lactobacillus paracasei, can be effectively used to create pharmaceutical or functional health-improving products for treating and preventing degenerative diseases, selected from a group consisting of mild cognitive disorders, dementia and Alzheimer's disease or neuropsychic stress.
17 cl, 16 dwg, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LACTOBACILLUS PLANTARUM STRAIN KBL396 AND APPLICATION THEREOF | 2019 |
|
RU2764639C1 |
| NEW LACTIC ACID BACTERIA AND THEIR USE | 2018 |
|
RU2778773C2 |
| NEW LACTIC ACID BACTERIA AND THEIR USE | 2018 |
|
RU2808245C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING DEGENERATIVE BRAIN DISEASE COMPRISING GLYCINE TRANSPORTER AS ACTIVE INGREDIENT | 2021 |
|
RU2816256C1 |
| COMPOSITION, CONTAINING MIXED EXTRACT OF MULBERRY AND PORIA COCOS SKIN, INTENDED FOR PREVENTION, RELIEF AND TREATMENT OF NEURODEGENERATIVE DISORDERS | 2015 |
|
RU2679654C2 |
| TREATMENT OF NEUROLOGICAL DYSFUNCTION BY USING FRUCTOPYRANOSE AND ERYTHROPOIETIN SULFAMATES | 2002 |
|
RU2317086C2 |
| COMPOSITION, CONTAINING EXTRACT OF PORIA COCOSUM TISSUE, INTENDED FOR PREVENTION, RELIEF AND TREATMENT OF NEURODEGENERATIVE DISORDERS | 2015 |
|
RU2678982C2 |
| VESICLES OBTAINED FROM LACTOBACILLUS PARACASEI AND THEIR USE | 2019 |
|
RU2785709C2 |
| TREATMENT METHOD FOR AMYOTROPHIC LATERAL SCLEROSIS | 2023 |
|
RU2804196C1 |
| AGONISTS OF NEUROTROPHIN RECEPTORS AND THEIR USE AS MEDICAMENTS | 2011 |
|
RU2606622C2 |
